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1  |  INTRODUC TION
Turner syndrome (TS) is a chromosomal disorder caused by an ab-
normal or missing second X chromosome in a phenotypic female. 
Cardinal features of TS are short stature and primary ovarian insuffi-
ciency leading to failure in onset and progression of secondary sex-
ual characteristics. At adult height, untreated women are an average 
of 21 cm shorter than their peers,1 while girls receiving recombinant 
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Objective: Short stature in Turner syndrome (TS) may be accompanied by skeletal 
disproportion. This retrospective study investigates growth and disproportion from 
early childhood to adult height.
Study design: Data were collected from 59 girls prior to growth hormone (rhGH) 
treatment and in 30 girls followed up longitudinally. Standard deviation scores (SDS) 
for height (Ht), sitting height (SH) and sub- ischial leg length (LL) were compared and a 
disproportion score (SH SDS – LL SDS) calculated.
Results: In 59 girls, mean (SD) age 6.6 (2.1) years prior to rhGH treatment, LL SDS of 
−3.4 (1.1) was significantly lower than SH SDS of −1.2 (0.8) [p < .001]. In girls with Ht 
SDS < −2.0, disproportion score was > +2.0 in 27 (63%), cf eight (50%) with Ht SDS ≥ 
−2.0. For the longitudinal analysis, skeletal disproportion prior to rhGH was +2.4 (1.1) 
and +1.7 (1.0) on rhGH but prior to introduction of oestrogen [p < .001]. Disproportion 
at adult height was +1.1 (0.8), which was less marked than at the earlier time points 
[p < .001 for both comparisons]. Change in disproportion SDS over the first two years 
of rhGH predicted overall change in disproportion from baseline to adult height [R2 
51.7%, p < .001].
Conclusion: TS is associated with skeletal disproportion, which is more severe in the 
shortest girls and present in only half of those with milder degrees of short stature. 
Growth- promoting therapy may improve disproportion during both the childhood and 
pubertal phases of growth. Change in disproportion status two years after starting 
rhGH helps predict disproportion at adult height.
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human growth hormone (rhGH) can expect at least 5 cm of height 
gain.2
A proportion of girls with TS continue to be diagnosed beyond 
early childhood, with significant numbers presenting in adolescence. 
Previous studies have reported delays in diagnosis, with up to 22% 
of cases identified beyond the age of 12 years.3,4 Girls presenting 
late often have the largest height deficit, while an earlier start of 
rhGH may lead to a greater gain in height.2,5 Earlier diagnosis allows 
screening for other health problems associated with TS, for appro-
priate timing of pubertal induction and for counselling of future 
issues with fertility, while late diagnosis is associated with poorer 
psychosocial adjustment.6
Short stature in girls with TS is partly explained by haploinsuffi-
ciency in the short stature homeobox- containing gene (SHOX), which 
is critical to growth promotion. The SHOX gene is located on the 
short arm of the X chromosome and is spared from X- inactivation 
in the normal female embryo. Cohorts of children with SHOX dele-
tions have been studied, and phenotypic similarities with TS have 
been identified.7 Children with SHOX deletions are disproportionate 
as well as short, with short limbs but a near- normal sitting height.8 
Similar skeletal disproportion may exist in TS and could perhaps aid 
in achieving an earlier diagnosis in those with a milder degree of 
short stature. The effect of growth, rhGH and oestrogen therapy on 
skeletal disproportion in TS is unclear.
The aim of this study was to describe skeletal proportions in girls 
with TS prior to any growth- promoting therapies and evaluate the 
change in proportions over time in relation to growth, rhGH therapy 
and pubertal induction with oestrogen.
2  |  SUBJEC TS AND METHODS
2.1  |  Subjects
This retrospective study involved analysis of routinely collected 
data as part of a clinical evaluation of the TS clinic. Case notes of 
157 girls born from 1976, who attended a designated TS clinic at 
the Royal Hospital for Children, Glasgow, between 1990 and 2015 
were reviewed. All girls had genetically confirmed TS karyotype 
by cytogenetic analysis of lymphocyte culture, with at least 20 
cells counted. Girls were excluded if they had any other second-
ary chronic medical condition that may affect growth by last clinic 
visit (including hypothyroidism and coeliac disease) and if they did 
not require rhGH or oestrogen therapy for pubertal induction or 
hormone replacement.
2.2  |  Methods
Out of the 157 girls, 59 girls had height (Ht) and sitting height (SH) 
measured at a routine outpatient clinic visit prior to any growth- 
promoting therapy and were at least four years of age prior to 
treatment with rhGH. Sub- ischial leg length (LL) was obtained from 
measured Ht minus measured SH. Out of the 59 girls, 30 had serial 
measurements up to the attainment of final height to evaluate the 
impact of rhGH and oestrogen therapy. For these 30 girls, the last 
visit prior to introduction of oestrogen therapy or prior to signs of 
spontaneous puberty after 10 years of age was taken as the pre- 
pubertal measurement. Subjects were deemed to have reached adult 
height when height velocity was less than 1 cm per year (or 2 cm 
over two years where data were incomplete due to missed outpa-
tient appointments).
Standard deviation scores (SDS) for Ht, SH and LL were calcu-
lated using the LMSgrowth application and the British 1990 ref-
erence population.9 Skeletal disproportion was quantified using a 
disproportion score: sitting height SDS minus leg length SDS (SH 
SDS – LL SDS).10 A subject with a relatively lower sitting height will 
have a lower, negative SH SDS – LL SDS, whereas a subject with a 
relatively lower leg length will have a higher, positive SH SDS – LL 
SDS. For example, an individual with SH SDS of −3.0 and LL SDS of 
−2.0 will have SH SDS – LL SDS of −1.0, indicating a relatively short 
back, while SH SDS of −2.0 and LL SDS of −3.0 gives SH SDS – LL 
SDS of +1.0, indicating relatively short legs. This difference can be 
considered a standard deviation score in its own right (the standard 
deviation of the SDS difference is close to one11), allowing it to be 
viewed in context with the standard deviation scores for Ht, SH 
and LL.
Recombinant human growth hormone (rhGH) via daily injections 
was administered at a dose of 0.3 mg/kg/week. Oestrogen in the form 
of ethinyloestradiol was used for pubertal induction, commencing at 2 
micrograms (mcg) daily and building up to adult doses. Detailed descrip-
tions of our method of pubertal induction and hormone replacement 
have previously been published.12 In some girls, oxandrolone therapy 
was commenced at a dose of 0.05 mg/kg/day (maximum dose 2.5 mg 
daily) from the age of nine years, in conjunction with the use of rhGH.12
The association between change in height SDS following the first 
two years of rhGH and change in height SDS from the baseline mea-
surement to adult height was analysed in the 26 girls in whom these 
data were available. In this group, the association between change 
in disproportion SDS over the first two years on rhGH and overall 
change in disproportion SDS was also analysed. IGF- 1 data were not 
analysed since this hormone had not been measured systematically 
during the study period.
2.3  |  Statistical analysis
Auxological parameters were normally distributed, and so descriptive 
data were expressed as mean (standard deviation). Differences were 
analysed using one- sample, two- sample and paired t tests where ap-
propriate, and using chi- square analysis for categorical data, with sta-
tistical significance set at less than 0.05. The impact of various factors 
on skeletal disproportions at adult height was assessed by linear regres-
sion analysis. The Bonferroni method was used to adjust for multiple 
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comparisons, giving a 99% adjusted confidence interval for the serial 
measurements and for the regression analysis displayed in Table 1.
2.4  |  Ethical approval
This study did not require ethical approval or informed consent as 
it was conducted as part of healthcare evaluation of routine clinical 
practice and according to national guidance.
3  |  RESULTS
3.1  |  Baseline measurements, prior to rhGH
Mean age at first sitting height measurement was 6.6 (2.1) years. 
Out of the 59 subjects, a specific karyotype was recorded for 57 
girls: 45,X (19); 45,X/46,XiXq (15); 45,X/46,XY (4); 45,X/47,XXX (4), 
45,X/46,XX (3); and others (including structural anomalies) (12). The 
two remaining subjects had a karyotype confirming TS but we were 
unable to attain records of the specific karyotype. These subjects 
are known not to have undergone gonadectomy and therefore can 
be assumed to have had no Y material detected. Mean Ht SDS at first 
measurement was −2.6 (0.9), while LL SDS of −3.4 (1.1) was lower 
than mean SH SDS of −1.2 (0.8) [p < .001; Figure 1A]. Mean SH SDS 
– LL SDS was + 2.2 (1.1), which was significantly greater than zero 
[p < .001; Figure 1B]. Out of the 59 girls, 35 (59%) had a dispropor-
tion score greater than +2.0. There was no difference in dispropor-
tion in those girls with 45,X karyotype, +2.5 (1.1), compared with 
other karyotypes, +2.0 (1.0) [p = .10], or between those with a Y 
chromosome, +1.6 (1.2), compared with the rest of our subjects, +2.2 
(1.1) [p = .37]. No orthopaedic problems, including progressive varus 
deformity of the proximal tibia, were recorded in the study patients.
In a multiple regression analysis, with Ht SDS and age as indepen-
dent factors, only Ht SDS was significantly associated with skeletal 
disproportion [p = .01, 95% confidence interval (CI): −0.68 to −0.10]. 
This indicates that disproportion is greater in shorter girls and that 
variability in stature is driven more by differences in leg length than 
in trunk length. In those girls with a Ht SDS of less than −2.0, 27 
(63%) had a disproportion score greater than +2.0, compared with 
eight (50%) of those with a Ht SDS of −2.0 or greater [p = .37].
3.2  |  Longitudinal changes in growth with rhGH, 
oxandrolone and oestrogen treatment
In 30 girls, measurements were available at each time point of 
interest— prior to rhGH treatment, pre- pubertal prior to introduction 
SH SDS– LL SDS
R2 p β 99% CI
Age at starting rhGH 2.6 0.4 +0.06 - 0.14, +0.26
Age at starting synthetic 
oestrogen
3.1 0.4 - 0.09 - 0.38, +0.19
Change in height SDS 
following two years of 
rhGH
<0.1 0.9 +0.01 - 1.01, +1.04
Length of rhGH therapy 
prior to synthetic 
oestrogen
4.1 0.3 - 0.05 - 0.20, +0.09
Karyotype 2.8 0.4 +0.28 - 0.62, +1.18
Disproportion prior to rhGH 37.4 <0.001 +0.48 +0.14, +0.82
Final height 10.0 0.09 - 0.05 - 0.13, +0.03
Abbreviation: rhGH, recombinant human growth hormone.
TA B L E  1  Univariate regression analysis 
for predictors of skeletal disproportion 
at final height, as measured by the 
disproportion score: difference in sitting 
height and sub- ischial leg length standard 
deviation scores (SH SDS – LL SDS)
F I G U R E  1  (A, B) Body proportions in 59 girls with Turner 
syndrome prior to recombinant human growth hormone therapy, 
showing height (Ht), sitting height (SH) and sub- ischial leg length 
(LL) standard deviation score (SDS) (A); and the disproportion score 
– SH SDS minus LL SDS (B)






















800  |    MCVEY Et al.
of oestrogen and at final height (Figure 2A,B). For this longitudinal 
analysis, mean age was 6.5 (2.1) years prior to rhGH treatment, 12.5 
(1.5) years pre- pubertal prior to introduction of oestrogen and 18.0 
(1.0) years at attainment of final height. Of the 30 girls, 18 (60%) 
were treated with oxandrolone, commencing at 12.6 (2.2) years. 
Mean duration of oxandrolone therapy was 3.0 (1.4) years. Of the 
18 treated with oxandrolone, 12 (67%) received oxandrolone prior 
to introduction of oestrogen.
Mean Ht SDS prior to rhGH was −2.7 (0.8). After 5.8 (3.2) 
years of rhGH treatment, mean Ht SDS was −2.2 (0.8) at the pre- 
pubertal measurement, prior to introduction of oestrogen therapy 
[p = .001]. Mean adult height SDS was −1.9 (0.9), which was greater 
than both of the other timepoints [p < .001 vs. baseline, p = .009 
vs. pre- pubertal].
Figure 2A,B shows differences in SH SDS and LL SDS with fol-
low- up. Mean SH SDS was not different between baseline and the 
assessment prior to commencement of oestrogen therapy at −1.1 
(0.6) and −1.3 (0.6), respectively [p = .23]. At attainment of adult 
height, mean SH SDS was −1.0 (0.7), which was also not different 
from baseline [p = .37]. However, there was significant difference 
between the measurement prior to oestrogen therapy and adult 
height [p = .002]. Mean LL SDS prior to rhGH was −3.6 (1.1), and this 
was −3.0 (1.0) after rhGH treatment but prior to introduction of oes-
trogen [p < .001]. Mean LL SDS at adult height was −2.1 (1.0), which 
was significantly different compared with the two other timepoints 
[p < .001 for both comparisons].
3.3  |  Changes in disproportion score with follow- 
up
Prior to rhGH, mean disproportion score was +2.4 (1.0), decreasing 
to +1.7 (1.0) after rhGH treatment but prior to introduction of oes-
trogen [p < .001] (Figure 3). Disproportion at adult height was +1.1 
(0.8) which was significantly lower compared with the other two 
timepoints [p < .001 for both comparisons]. Out of the 30 girls, 
three (10%) had a disproportion score of +2.0 or greater at adult 
height.
3.4  |  Factors associated with adult height and 
disproportion
To evaluate factors associated with skeletal proportions at adult 
height, univariate linear regression was performed. Table 1 shows 
regression analysis with SH SDS – LL SDS as the dependent factor. 
Disproportion at adult height was not associated with age of start-
ing rhGH, age of starting oestrogen, improvement in height SDS fol-
lowing the first two years of rhGH, pre- pubertal duration of rhGH, 
karyotype (45,X vs others) or adult height. However, disproportion 
at adult height was associated with disproportion prior to rhGH 
[p < .001]. Change in height SDS from the initial measurement to 
final adult height was associated with change in height SDS during 
the first two years of rhGH therapy [R2 26.1%, p = .008, β 0.77, 95% 
CI (+0.23, +1.32)]. Similarly, change in skeletal disproportion SDS 
from the baseline measurement to adult height was associated with 
the change in disproportion measured over the first two years of 
treatment with rhGH [R2 51.7%, p < .001, β 0.56, 95% CI (+0.34, 
+0.77)].
4  |  DISCUSSION
This study confirms the finding of abnormal body proportions in chil-
dren with TS, with disproportionately shorter legs compared with 
trunks,13- 15 and adds detail to our knowledge of change in proportions 
during rhGH- promoted growth. Our analysis is important in that we 
studied a unique cohort of patients who were followed up in one ter-
tiary centre clinic dedicated for TS patients, and also that our subjects 
had no other underlying co- morbidities that may impact on growth. 
We have clearly separated the phases of growth and have shown 
for the first time using longitudinal data that skeletal disproportion 
(SH SDS – LL SDS) was less marked by the end of childhood growth 
and largely resolved at adult height with rhGH therapy and puberty. 
Our results support published data on less marked disproportion in 
adults with TS but also provide more detail on longitudinal changes 
in growth with rhGH, and oestrogen therapy.14,16 While improvement 
in height during the first two years of rhGH therapy did not predict 
F I G U R E  2  (A, B) Differences in sitting height (SH) and sub- ischial leg length (LL) standard deviation scores (SDS) in 30 girls with Turner 
syndrome treated with recombinant human growth hormone (rhGH) and oestrogen therapy. SH SDS and LL SDS were assessed at three time 
points: prior to rhGH therapy (pre- rhGH), prior to oestrogen therapy (pre- pubertal stage) and at final height
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adult disproportion in the individual patient, we found that changes in 
height and disproportion over this time period were highly predictive 
of the overall change in height and disproportion from commencement 
of rhGH to final adult height. Apart from its retrospective design, our 
study findings are limited by the absence of an untreated group of girls 
with Turner syndrome, against whom changes in growth and dispro-
portion attributable to growth- promoting therapy could be evaluated. 
In practice, however, it would have been difficult to justify denying 
rhGH treatment to short girls with TS during the study period, and this 
ethical constraint would apply to any future prospective study.
In our cohort, in early childhood, approximately 60% of girls 
with TS had SH SDS – LL SDS > +2.0, an indicator of skeletal dis-
proportion. This is consistent with published literature in TS, but 
our prevalence is lower than the almost 90% disproportion seen 
with SHOX deficiency.13 While disproportion in TS has been pre-
viously reported,13- 15 it is unclear if these studies excluded those 
with other underlying chronic conditions that may affect growth. 
In TS, SHOX haploinsufficiency is thought to be largely respon-
sible for short stature and skeletal abnormalities. SHOX is highly 
expressed in multiple tissues, and studies in the human foetal 
growth plate and in adolescents have shown that it is identified 
predominantly in the hypertrophic zone.17,18 It is mainly confined 
to the distal ends of the humerus, radius, ulna and lower limb 
bones, as well as the maxilla, mandible, first and second pharyn-
geal arches.19 It is therefore logical that SHOX insufficiency should 
have a greater impact on the growth of the limbs rather than on 
the axial skeleton, leading to skeletal disproportion, as our results 
illustrate. We were unable, in this retrospective study, to inves-
tigate a correlation between features of skeletal dysplasia con-
sistent with SHOX haploinsufficiency and the severity of skeletal 
disproportion. This possible association should inform the design 
of a future prospective study.
Late diagnosis of TS still occurs, with approximately 20% diag-
nosed in adolescence and adulthood.3,4,20 It is clinical convention 
that a screening karyotype should be performed in all short girls.21 
However, interpreting height in the parental context may be more 
specific for the diagnosis of TS, especially with a girl who is relatively 
tall.22 We hypothesized that skeletal disproportion in a girl with a 
milder degree of short stature may be an additional clue to raise clin-
ical suspicion of TS. Our results, however, showed that only about 
50% of girls with milder degrees of short stature had evidence of 
skeletal disproportion defined by SH SDS – LL SDS > +2.0, meaning 
that this skeletal disproportion index (SH SDS – LL SDS) is unlikely 
to be a helpful diagnostic clue based on the threshold we used in 
our analysis. We found no difference in disproportion between the 
subgroups of karyotype we assessed, although patient numbers in 
this sub- analysis were small. It would be interesting to further eval-
uate the effect of karyotype on disproportion in a larger cohort of 
patients.
Our longitudinal analysis showed that there was some im-
provement in skeletal disproportion following an average of six 
years of rhGH therapy prior to pubertal induction with oestrogen, 
and disproportion resolved by adult height. On the other hand, in 
a dose- response trial of rhGH in 68 girls with TS, where subjects 
were randomized to three groups, receiving varied doses of rhGH 
(ranging from 4 to 8 IU/m2 of rhGH), skeletal disproportion did 
not improve after the first seven years of rhGH. Changes in dis-
proportion did not appear to be related to the dose of rhGH.14 In 
another study of 73 girls and 120 women with TS, where around 
one third had received rhGH, disproportion was less frequent at 
adult height but did not differ regardless of whether rhGH therapy 
was administered.13 However, both of these studies used mea-
sures of disproportion based on the relationship between sitting 
height and height, which could impact on the interpretation of 
their results. The ratio between sitting height and height will be 
inherently greater in shortest girls due to the statistical concept 
of regression to the mean. Thus, when a girl has one very extreme 
measurement, for example extreme short stature, then by the law 
of averages, other measurements are likely to be less extreme and 
closer to the population mean (causing sitting height to be propor-
tionately greater). This strong inverse relationship between height 
and the sitting height- to- height ratio could then skew results. The 
disproportion score used in our study avoids the confounding fac-
tor of height and focusses solely on disproportion itself, leading to 
more reliable results.
In addition to our other analysis, we studied various factors that 
might help predict skeletal proportions at final adult height, fol-
lowing a course of rhGH and synthetic oestrogen. Our data show 
that while childhood disproportion predicts adult disproportion, 
improvement in height SDS during the first two years of rhGH does 
not predict disproportion at adult height. By contrast, height SDS 
increase over the first two years of rhGH was predictive of over-
all increase in height SDS on rhGH, in keeping with findings from 
previous trials.23 Additionally, we have shown for the first time that 
change in skeletal disproportion over the first two years of rhGH is 
predictive of overall change in disproportion from commencement 
F I G U R E  3  Differences in disproportion score in 30 girls with 
Turner syndrome receiving recombinant human growth hormone 
(rhGH) and oestrogen therapy. Disproportion score (sitting height 
standard deviation score (SH SDS) minus sub- ischial leg length 
standard deviation score (LL SDS)) was assessed at three time 
points: prior to rhGH therapy (pre- rhGH), prior to oestrogen 
therapy (pre- pubertal stage) and at final height
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of rhGH to final height. Thus, two years after starting rhGH ap-
pears a valuable time point for assessing growth status and pre-
dicting the changes in growth and disproportion that an individual 
patient is likely to experience on treatment. Others have found 
no association between final adult height and factors such as age 
at commencing rhGH, duration of therapy or age at commencing 
synthetic oestrogen,24 and similarly, we have found no association 
between these factors and disproportion at final height.
We found that skeletal disproportion was less marked at adult 
height following rhGH therapy and pubertal induction. While some 
of our subjects with TS were commenced on oxandrolone prior to 
oestrogen therapy, a previous study from a randomized trial of oxan-
drolone in TS did not show any effect on body proportions.16
The majority of patients with TS require synthetic oestrogen for 
induction of puberty, including all of the subjects included in our 
study.12 Previous evidence on the effect of synthetic oestrogen on 
skeletal disproportion is limited. In a UK study, disproportion was 
not different between 16 girls with TS who did not receive oes-
trogen and six girls who have received oestrogen when evaluated 
at a median age of 13.8 years (range 9 to 19.5 years).25 A cohort 
of Danish adult women with TS who had not received rhGH but 
were treated with oestrogen did not exhibit disproportion at adult 
height.26 Our longitudinal analysis identified ongoing improvement 
in disproportion score following oestrogen therapy. The average re-
duction in disproportion score following rhGH therapy (−0.7 SD) and 
oestrogen therapy (−0.6 SD) was relatively similar in our analysis. 
Our results and those of published evidence do not allow us to draw 
conclusions on factors which contribute to the less marked dispro-
portion at adult height in TS. It is of course possible that this is the 
natural evolution in untreated people with TS. However, taken to-
gether, our results and those of published data provide reassurance 
that the current treatment regimen of promoting growth and manag-
ing hypogonadism in these girls does not enhance disproportion and 
may indeed help to lessen it.
5  |  CONCLUSION
Skeletal disproportion is prominent in untreated young girls with 
TS, with reduced leg length. This is more severe in the short-
est girls and is present in only half of those with milder degrees 
of short stature. Our data provide reassurance that growth- 
promoting therapy has no adverse effect on, and may improve, 
this disproportion. Change in height and disproportion status two 
years after starting rhGH helps predict adult height and degree of 
disproportion, indicating that this is a useful time point to gauge 
treatment responsiveness.
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